About the expert

Martin Gamble is Shares and Markets writer at AJ Bell. He was previously the Education Editor of Shares Magazine. He has been with the business since 2019.

Martin graduated from the University of Kent in 1984 with an accounting degree.

He has extensive financial markets experience gained through managing UK and European equity portfolios for institutions including Hermes Investment Management, Manulife Financial and Royal Bank of Canada.

While at Manulife Financial the funds Martin managed were consistently in the top quartile which was recognised with a ‘Stars of Excellence’ award.

Martin subsequently headed up the fund management business for Royal Bank of Canada in London.

Outside of work, Martin likes long distance hiking and playing Backgammon.

Latest articles from Martin Gamble

  • 29 May 2026

    Discover the cheapest and priciest global markets

    Valuations in investing are often relative, with different stocks or entire markets looking cheap or expensive compared with their peers. We’ve carried out some analysis on valuations across international markets to reveal the cheapest and most expensive, based on consensus forecast earnings complied by LSEG.

    For each individual market LSEG...

    5 min read
    Image representing emerging markets
  • 27 May 2026

    Discover the FTSE 100’s biggest earnings growers

    The FTSE 100 has a reputation for being low growth and stodgy, dominated by large mining companies and financials. While partially true, there are also some faster growing ‘gems’ hiding in plain sight.

    This article identifies a selection of companies which have consistently grown earnings at more than a double-digit rate for two decades. These...

    5 min read
    Stock chart
  • 24 May 2026

    Do you own Microsoft? Discover the opposing views of two managers

    It is not unusual for fund managers to have different views on stocks, but when two high profile managers make opposing bets, it certainly grabs the attention.

    Regulatory filings show TCI (The Children’s Fund) founder Chris Hohn sold virtually all its $8 billion stake in US software giant Microsoft and subsequently increased its stake in Alphabet...

    4 min read
    Outside the Microsoft headquarters in Washington
  • 20 May 2026

    Which sectors outperformed when interest rates rose

    The yield on 10-year UK government bonds recently pushed through the key 5% mark to reach their highest levels since the late 1990s while 30-year yields are approaching 6%.

    While this kind of environment is not typically helpful for stocks, some parts of the market have historically done better than others when rates are rising.

    The UK is not alone...

    6 min read
    Geopolitical composite image
  • 20 May 2026

    Discover the story behind two attempts to value soaraway US stocks

    At first glance, US stocks look fully valued based on traditional valuation metrics like the PE (price to earnings) ratio, but a new study by researchers at the Federal Reserve of Minneapolis suggests equity markets may be somewhat less expensive than generally thought.

    This article ‘unpacks’ the new research to explain the key differences between...

    8 min read
    Shares magazine
    Image representing US stocks
  • 15 May 2026

    The neat trick which could help turn £1,000 into £20,000

    This article shows how the power of reinvesting dividends can really growth wealth over the long run. While this is purely an illustrative example and nothing in investing is guaranteed it helps show the difference this investment approach can make.

    While we use the example of a single company for simplicity, it is crucial that investors hold a...

    4 min read
    Woman with a mobile phone
  • 14 May 2026

    Can Novo Nordisk regain its place in the weight-loss race?

    Danish healthcare company Novo Nordisk remains one of Europe’s largest companies by market value despite the shares falling 70% over the last two years.

    The fall from grace was preceded by a 540% advance in the shares following US regulatory approval for Novo’s diabetes treatment Ozempic in late 2017.

    Novo launched the world’s first treatment for...

    7 min read
    Shares magazine
    Wegovy injection pen